Satellos Bioscience Inc.: Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights

Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics

Related Keywords

United States ,Canada ,Sherbrooke ,Quebec ,Toronto ,Ontario ,United Kingdom ,Canadian ,British ,Ryan Mitchell ,Christina Cameron ,Frank Gleeson ,Michael Rudnicki ,Phil Lambert ,Technology Officer ,World Muscle Society Congress ,Communications At Satellos Bioscience Inc ,Business Development ,Newsfile Corp ,Co Arrangement ,Satellos Bioscience Inc ,Research Agreement ,Disease Expansion Indication ,Congenital Muscular Dystrophy Type ,Sponsored Research Agreement ,Chief Technology ,British Columbia ,Listing Expense ,Satellos Bioscience ,Satellos ,Ioscience ,Nnounces ,022 ,Ear ,Financial ,Results ,Perational ,Highlights ,